Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal Of The American Academy Of Dermatology 2017, 77: 88-97.e5. PMID: 28495497, DOI: 10.1016/j.jaad.2017.01.037.Peer-Reviewed Original ResearchConceptsChronic HBV infectionBiologic therapyHBV infectionViral reactivationAntiviral prophylaxisCore antibodyHCV infectionHepatitis BSafety of biologic therapiesHistory of viral hepatitisSystematic reviewIsolated core antibodyHBV core antibodyLow-risk patientsRetrospective cohort study designRetrospective cohort studyReactivated HBV infectionCohort study designPsoriasis patientsViral hepatitisEvaluate safetyFollow-upCohort studyPrimary outcomeTreatment duration